Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
EMERYVILLE, Calif., May 02, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences:
- Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled to present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 2:50 p.m. EDT
- Richard A. King, the company’s Chief Operating Officer, is scheduled to present at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 at 1:40 p.m. PDT
The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. Archived versions of the webcasts will be available via replay for 30 days following the presentations.
About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.
Contact:
Investors:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
[email protected]
Media:
Terri Clevenger
Continuum Health Communications
203-227-0209
[email protected]
